3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Burkitt Lymphoma
5
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Prostate Cancer Recurrent
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Multiple Myeloma
1
Melanoma
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Biphenotypic, Acute
1
Hematologic Neoplasms
1
Glioma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Imatinib Mesylate
4
Sunitinib
3
Specimen Handling
2
Magnetic Resonance Spectroscopy
2
trastuzumab deruxtecan
1
ripretinib
1
pemigatinib
1
Surgical Instruments
1
Rogaratinib
1
Nivolumab
1
Midazolam
1
Ipilimumab
1
IDRX-42
1
CTLA-4 Antigen
1
Biopsy
1
4-Aminopyridine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
Dasatinib
×
30 days
×
Clear all
No trials found.